Clozapine response in early treatment-resistant schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 1, Issue 4, 1997, Pages 261-268

  Joffe, Grigori ^a   Rybak, Juri ^b   Burkin, Mark ^b   Burkin, Dmitri ^b   Appelberg, Björn ^a   Joffe, Marina ^a   Gädeke, Rainer ^a   Rimon, Ranan ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b PETROZAVODSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Clozapine; Treatment resistance time factor

Indexed keywords

EID: 0001758203     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509709024737     Document Type: Article

References (37)

1. McEvoy J, Hogarty G, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739-45.
2. Wyatt R (1991) Neuroleptics and natural course of schizophrenia. Schizophr Bull 17: 325-351.
3. Loebel A, Lieberman J, Alvir J et al (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149: 1183-8.
4. Davis J, Schaffer C, Killian G et al (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 70-87.
5. Meltzer H (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18: 515-42.
6. Lieberman J, Koreen A (1993) Neurochemistry and neuroendocrinology of schizophrenia. Schizophr Bull 19: 371-429.
7. Olney J, Farber N (1994) Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry 55(suppl B): 43-46.
8. Nasrallah H, Skinner T, Schmalbrock P, Robitaille P (1994) Proton magnetic resonance spectroscopy (1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br J Psychiatry 165: 481-5.
9. Renshaw P, Yurgeluntodd D, Tohen M et al (1995) Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry 152: 444-6.
10. Stanley J, Williamson P, Drost D et al (1995) An in-vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 52: 399-406.
11. Horrobin D, Glen A, Vaddadi K (1994) The membrane hypothesis of schizophrenia. Schizophr Res 13: 195-207.
12. Lieberman J, Kinon B, Koebel A (1990) Dopaminergic mechanisms in idiopathic and drug-indused psychoses. Schizophr Bull 16: 97-110.
13. Lieberman J, Jody D, Geisler S et al (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50: 369-76.
14. Chouinard G (1991) Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5: 21-33.
15. Kane J, Honigfeld G, Singer J et al (1988) Clozapine for treatment-resistant schizophrenia. Arch Gen Psychiatry 45: 789-96.
16. Baidessarini R, Frankenburg F (1991) Clozapine: a novel antipsychotic agent. N Engl J A fed 324: 746-54.
17. Breier A, Buchanan R, Kirkpatrick B et al (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151: 20-26.
18. Kane J, Schooler N, Marder S et al (1996) Efficacy of clozapine versus haloperidol in a long-term clinical trial. Schizophr Res 18: 127.
19. Ekblom B, Häggström J (1974) Clozapine (Leponex®) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 16: 945-57.
20. Gerlach J, Koppelhus P, Helweg E et al (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50: 410-24.
21. Itoh H, Miura S, Yagi G et al (1977) Some methodological considerations for the clinical evaluation of neuroleptics -comparative effects of clozapine and haloperidol on schizophrenics. Folia Psychiatr Neurol Japonica 31: 17-24.
22. Shopsin B, Klein H, Aaronson M et al (1979) Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 36: 657-64.
23. Claghom J, Honigfeld G, Abuzzahab FS et al (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377-84.
24. Gelenberg A, Doller JC (1979) Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double blind study. J Clin Psychiatry 40: 238-40.
25. Amsler H, Teerenhovi L, Earth E et al (1977) Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 56: 241-48.
26. Idänpään-Heikkilä J, Alhava E, Olkinuora M et al (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11: 193-8.
27. May P, Dencker S, Hubbard J et al (1988) A systematic approach to treatment resistance in schizophrenic disorders. In: Treatment resistance in schizophrenia (eds S Dencker, F Kulhanek) 22-33. Vieweg, Braunschweig/Wiesbaden.
28. Szymanski S, Masiar S, Mayerhoff D et al (1994) Clozapine response in treatment-refractory first-episode schizophrenia. Biol Psychiatry 35: 278-80.
29. American Psychiatric Association (1987) DSM-III-R. Diagnostic and Statistical Manual of Mental Disorders. 3rd edn., revised. APA, Washington, DC.
30. Overall J, Gorham D (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10: 799-812.
31. Kay S, Fiszbein A, Opler (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-76.
32. Guy W (1976) ECDEU assessment manual for psychopathology (revised). 217-222. US Department of Health, Education and Welfare, Washington, DC.
33. Heinrichs D, Hanlon T, Carpenter W, Jr (1984) The Quality of Life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10: 388-98.
34. Simpson G, Angus J (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 45(Suppl. 212): 11-12.
35. Singer K, Law S (1974) A double-blind comparison of clozapine (Leponex) and chlorpromazine in schizophrenia of acute symptomatology. J Int Med Res 2: 433-5.
36. Klieser E, Strauss WH, Lemmer W (1994) The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiatr Scand 89: 68-73.
37. Joffe G, Venäläinen E, Tupala J et al (1996) The effect of clozapine on the course of illness in chronic schizophrenia: focus on treatment outcome in outpatients. Int Clin Psychopharmacol 11: 265-72.